RecallRadar

FDA Drug recall D-0853-2026

Dopamine HCl Inj., USP, 200 mg/5 mL (40 mg/mL), 5 mL Single-dose, 25 vials per tray, Rx only, Distributed by Hospira, Inc., Lake Forest, IL…

On 2026-09-23 the FDA classified a Class II recall of Dopamine HCl Inj., USP, 200 mg/5 mL (40 mg/mL), 5 mL Single-dose, 25 vials per tray, Rx only, Distributed by Hospira, Inc., Lake Forest, IL… by Pfizer, citing lack of Assurance of Sterility.

Read the official FDA Drug notice

AgencyFDA Drug
Recall numberD-0853-2026
ClassificationClass II
Statusongoing
Initiated2026-09-04
Published2026-09-23
Last updated2026-09-29 05:30 UTC
CompanyPfizer
DistributionUS

Product

Dopamine HCl Inj., USP, 200 mg/5 mL (40 mg/mL), 5 mL Single-dose, 25 vials per tray, Rx only, Distributed by Hospira, Inc., Lake Forest, IL 60045 USA, Vial NDC 0409-5820-11, Carton NDC 0409-5820-01.

Reason

Lack of Assurance of Sterility

Identifiers

ndc0409-5820-11
ndc0409-5820-01
ndc0409-9104-21
ndc0409-9104-20
code_infoLot # NL5230, Exp Date:10/2027

Status history

No status changes recorded since RecallRadar first saw this recall on 2026-09-29 05:30 UTC. Current status: ongoing.

Other recalls by Pfizer

All Pfizer recalls

Source

Official record: https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0853-2026%22

RecallRadar indexes public recall notices from the FDA, USDA FSIS, and CPSC. The official agency notice is the authoritative source. Always confirm details at the linked source before acting.